Physician profile
Gregory Brewer
NPI 1285621870
$8,459.28
in general payments reported to CMS, 2019-2025
26 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,488 · 2020: $2,419 · 2021: $1,320 · 2022: $1,469 · 2023: $42.46 · 2024: $386 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,029.55 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,160.12 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $809.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $753.84 | 2019-2024 | Wainua |
| Abbott Laboratories | $721.78 | 2019-2022 | |
| Amgen INC. | $475.67 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $455.99 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $394.22 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.41 | 2019-2024 | Jardiance |
| Pfizer INC. | $288.47 | 2019-2025 | |
| Esperion Therapeutics, INC. | $238.50 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $148.49 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $146.07 | 2019-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $110.44 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $84.74 | 2019-2024 | Opsumit, Uptravi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $43.56 | 2020 | |
| Biotronik INC. | $42.87 | 2019-2020 | |
| Bardy Diagnostics, INC. | $33.00 | 2020 | |
| Merck Sharp & Dohme LLC | $31.56 | 2021-2022 | |
| Scpharmaceuticals INC. | $30.71 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.49 | 2019 | |
| Lundbeck LLC | $20.01 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.98 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.25 | 2024 | |
| Portola Pharmaceuticals, LLC | $15.07 | 2019 | |
| Celonova Biosciences, INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.